Wall Street Zen upgraded shares of Braveheart Bio (NASDAQ:BRVE – Free Report) to a hold rating in a report published on Saturday.
Braveheart Bio Price Performance
BRVE opened at $27.66 on Friday. Braveheart Bio has a 12-month low of $24.61 and a 12-month high of $32.00.
Insider Buying and Selling
In other Braveheart Bio news, Director Erez Chimovits acquired 1,940,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the acquisition, the director owned 11,901,826 shares in the company, valued at $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Bio Fund Iv L.P. Ah bought 1,100,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the purchase, the insider directly owned 10,232,420 shares of the company’s stock, valued at approximately $184,183,560. This represents a 12.05% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 8,751,942 shares of company stock worth $157,534,956 over the last 90 days.
About Braveheart Bio
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
Featured Stories
- Five stocks we like better than Braveheart Bio
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.
